To include your compound in the COVID-19 Resource Center, submit it here.

Odanacatib: Phase III data

The double-blind, international Phase III LOFT trial in 19,713 postmenopausal women with osteoporosis who were receiving vitamin D and calcium showed that once-weekly 50 mg odanacatib met the co-primary endpoints of reducing the risk of osteoporotic hip fractures (47% relative risk reduction),

Read the full 424 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers